At Prometheus Laboratories Inc., we enable unique health solutions with novel diagnostics. As a leader of precision healthcare in gastroenterology, we develop and bring to market diagnostic tests that help physicians provide the highest level of patient care. Our commitment to innovation positions us for future growth and lays the foundation for expansion into new areas.
Every day our people and products earn the trust of patients and their families.
Every day our people and products earn the trust of patients and their families.
Location: United States, California, Sorrento Valley
Employees: 201-500
Founded date: 1995
Investors 1
| Date | Name | Website |
| - | Avista Cap... | avistacap.... |
Mentions in press and media 11
| Date | Title | Description |
| 11.05.2021 | Prometheus Laboratories Announces Multiple Presentations on Precision-Guided Dosing and Monitoring at the Digestive Disease Week 2021 Annual Meeting | |
| 11.03.2021 | Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering | |
| 10.09.2012 | Avista Capital Partners Appoints Brian A. Markison Healthcare Industry Executive | New York, NY, Sept. 10, 2012 – Avista Capital Partners today announced that Brian A. Markison has joined the firm as a healthcare Industry Executive. Mr. Markison has more than 30 years of experience in the pharmaceuticals sector, most rece... |
| 17.11.2011 | Salix IBS drug set to start second phase 3 trial in January | Clinical trial enrollment is set to start in January. Salix estimates it will take about two years to complete trials, resubmit a response to the FDA complete response letter and receive an approval decision. Salix said the proposed design ... |
| 17.12.2007 | Avista Capital Partners Agrees To Acquire Bristol-Myers Squibb Medical Imaging For Approximately $525 Million | New York, NY, December 17, 2007 – Bristol-Myers Squibb Company (NYSE: BMY) and Avista Capital Partners, a leading private equity firm, announced today the parties have signed a definitive agreement for Avista to acquire Bristol-Myers Squibb... |
| 13.12.2007 | Boston Scientific Agrees to Sell Fluid Management And Venous Access Business To Avista Capital Partners for $425 Million | Natick, MA and New York, NY December 13, 2007 – Boston Scientific Corporation (NYSE: BSX) and Avista Capital Partners, a leading private equity firm, today jointly announced the signing of a definitive agreement under which Avista will acqu... |
| 17.10.2007 | Avista Capital Partners bolsters healthcare practice with appointments of Charles Harwood and Ron Sparks | New York, NY, October 17, 2007 – Avista Capital Partners, a leading private equity firm, today announced that it has hired Charles C. Harwood, Jr., a proven operator in the clinical diagnostics and pharmaceutical services industries, and Ro... |
| 12.04.2007 | Avista Capital Partners completes acquisition Of Bioreliance Corporation from Invitrogen Corporation | New York, NY, April 12, 2007 – Avista Capital Partners, a leading private equity firm, announced today it has completed its acquisition of BioReliance Corporation, a business unit of Invitrogen Corporation (NASDAQ: IVGN) for approximately $... |
| 13.02.2007 | Avista Capital Partners agrees to acquire Bioreliance Corporation for approximately $210 million | New York, NY, February 13, 2007 – Avista Capital Partners, a leading private equity firm, announced today it has signed a definitive agreement to acquire BioReliance Corporation, a business unit of Invitrogen Corporation (NASDAQ: IVGN) for ... |
| - | Avista Capital Partners Appoints Hakan Bjorklund As Healthcare Operating Executive | Departing Nycomed CEO Bolsters Leading Private Equity Healthcare Practice New York, NY, October 3, 2011 – Avista Capital Partners, a leading private equity firm, today announced that it has hired Håkan Björklund, the departing Chief Execut... |
Show more